Skip to main content

Table 1 Characteristics of HIV-infected patients newly diagnosed with Kaposi’s sarcoma between 2009 and 2012 in a large community-based primary care network in Kenya

From: Real-world use of chemotherapy for Kaposi’s sarcoma in a large community-based HIV primary care system in Kenya

CharacteristicMedian (Interquartile range) or Percentage
(N = 588)
Age, years35 (30–42)
Male gender357 (61%)
Documented Symptoms at KS diagnosis
 Weight loss (self-reported)139 (24%)
 Diarrhea (self-reported)47 (8%)
 Night sweats56 (10%)
 Fever (self-reported or measured)107 (18%)
 ECOG performance status Mean (SD) a1.34 (0.80)
 ECOG > 172 (12%)
Extent of KS on skin
 Localized to one anatomic area115 (20%)
 More than localized257 (44%)
 Lymphadenopathy72 (12%)
 KS Lesions in oral cavity176 (30%)
 Interfering with swallowing30 (5.1%)
 GI KS suspected/confirmed30 (5.1%)
 Pulmonary KS suspected/confirmed51 (8.7%)
  > 1 Ulcerated KS lesion69 (12%)
 Edema N247 (42%)
 Interfering with function26 (4.4%)
 CD4+ T cells, count/μl b184 (68–350)
  < 5071 (12%)
 51–10048 (8.2%)
 101–20079 (13%)
 201–35080 (14%)
  > 35092 (16%)
Antiretroviral therapy (ART)
 On ART at time of diagnosis177 (30%)
 Days on ART among patients on ART at time of KS diagnosis119 (42–539)
 On ART > 60 days prior to KS diagnosis112 (19%)
Chemotherapy indication
 ACTG T1333 (57%)
 WHO “Severe KS”92 (16%)
Education
 None56 (10%)
 Primary346 (62%)
 Secondary135 (24%)
 Tertiary25 (4.4%)
Travel time to clinic
  < 30 min132 (23%)
 30–60 min193 (34%)
 1–2 h135 (23%)
  > 2 h115 (20%)
 Water piped into home74 (13%)
  1. aECOG = Eastern Cooperative Oncology Group performance status
  2. bCD4 count proximal to diagnosis was defined as the closest CD4 count to the date of KS diagnosis within a window from 30 days prior to diagnosis or up to 60 days after the diagnosis date. There was no proximal CD4 count available on 218 of the participants